IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation

References

• Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–17. doi:10.1038/s41571-020-0352-8.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. doi:10.1038/s41568-019-0116-x.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–55. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Ginefra P, Lorusso G, Vannini N. Innate immune cells and their contribution to T-Cell-Based Immunotherapy. Int J Mol Sci. 2020;21(12):4441. doi:10.3390/ijms21124441.
   PubMed Web of Science ®Google Scholar
• Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18):e93397. doi:10.1172/jci.insight.93397.
   PubMed Web of Science ®Google Scholar
• Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019;290(1):24–38. doi:10.1111/imr.12765.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Brody J, Ingham M, Strauss J, Cemerski S, Wang M, Tse A, Khilnani A, Marabelle A, Golan T. LBA15 Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol. 2018;29(viii 712):viii712. doi:10.1093/annonc/mdy424.015.
   Google Scholar
• Pero SC, Rosenfeld AM, Shukla GS, Mei L, Sun Y, Meng W, Fournier DJ, Harlow SP, Robinson MK, Krag DN, et al. Diversification and shared features of tumor‐binding antibody repertoires in tumor, sentinel lymph node and blood of three patients with breast cancer. Clin Transl Immunol. 2022;11(8):e1409. doi:10.1002/cti2.1409.
   Web of Science ®Google Scholar
• Khan TA, Friedensohn S, de VA, Straszewski J, Ruscheweyh H-J, Reddy ST. Accurate and predictive antibody repertoire profiling by molecular amplification fingerprinting. Sci Adv. 2016;2(3):e1501371. doi:10.1126/sciadv.1501371.
   PubMed Web of Science ®Google Scholar
• DiMuzio JM, Heimbach BC, Howanski RJ, Dowling JP, Patel NB, Henriquez N, Nicolescu C, Nath M, Polley A, Bingaman JL, et al. Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine: X. 2021;8:100098. doi:10.1016/j.jvacx.2021.100098.
   PubMedGoogle Scholar
• Nikitin PA, DiMuzio JM, Dowling JP, Patel NB, Bingaman-Steele JL, Heimbach BC, Henriquez N, Nicolescu C, Polley A, Sikorski EL, et al. IMM-BCP-01, a patient-derived anti–SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. Sci Immunol. 2022;7(75):eabl9943. doi:10.1126/sciimmunol.abl9943.
   PubMed Web of Science ®Google Scholar
• Baker KJ, Houston A, Brint E. IL-1 family members in cancer; two sides to every story. Front Immunol. 2019;10:1197. doi:10.3389/fimmu.2019.01197.
   PubMed Web of Science ®Google Scholar
• van Devan de VF, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LAB, van der MJ, Hao R, Kalabokis V, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc National Acad Sci. 2012;109(8):3001–05. doi:10.1073/pnas.1121534109.
   PubMed Web of Science ®Google Scholar
• Mora J, Schlemmer A, Wittig I, Richter F, Putyrski M, Frank A-C, Han Y, Jung M, Ernst A, Weigert A, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8(5):426–38. doi:10.1093/jmcb/mjw006.
   PubMed Web of Science ®Google Scholar
• Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ, Doti N, Pagnanelli G, Gubinelli E, Mazzanti C, Cavani A, Ruvo M, et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death & Disease. 2018;9(11):1104. doi:10.1038/s41419-018-1143-3.
   PubMed Web of Science ®Google Scholar
• Han Y, Mora J, Huard A, da SP, Wiechmann S, Putyrski M, Schuster C, Elwakeel E, Lang G, Scholz A, et al. IL-38 ameliorates skin inflammation and limits IL-17 production from γδ T cells. Cell Rep. 2019;27(3):835–46.e5. doi:10.1016/j.celrep.2019.03.082.
   PubMed Web of Science ®Google Scholar
• de GD, Wang RX, Amo-Aparicio J, Lee JS, Dowdell AS, Tengesdal IW, Marchetti C, Colgan SP, Joosten LAB, Dinarello CA. IL-38 gene deletion worsens murine colitis. Front Immunol. 2022;13:840719. doi:10.3389/fimmu.2022.840719.
   PubMed Web of Science ®Google Scholar
• Kinoshita F, Tagawa T, Akamine T, Takada K, Yamada Y, Oku Y, Kosai K, Ono Y, Tanaka K, Wakasu S, et al. Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment. Cancer Immunol Immunother. 2021;70(1):123–35. doi:10.1007/s00262-020-02659-9.
   PubMed Web of Science ®Google Scholar
• Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S, Katsura M, Toyokawa G, Shoji F, Okamoto M, et al. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: possible association with PD-L1 expression. PLos One. 2017;12(7):e0181598. doi:10.1371/journal.pone.0181598.
   PubMed Web of Science ®Google Scholar
• Luheshi NM, Rothwell NJ, Brough D. The dynamics and mechanisms of interleukin-1α and β nuclear import. Traffic Cph Den. 2008;10(1):16–25. doi:10.1111/j.1600-0854.2008.00840.x.
   PubMed Web of Science ®Google Scholar
• Diaz-Barreiro A, Huard A, Palmer G. Multifaceted roles of IL-38 in inflammation and cancer. Cytokine. 2022;151:155808.
   PubMed Web of Science ®Google Scholar
• Xie L, Huang Z, Li H, Liu X, Zheng S, Su W. IL-38: a new player in inflammatory autoimmune disorders. Biomol. 2019;9(8):345. doi:10.3390/biom9080345.
   Google Scholar
• Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC. Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol Res. 2018;6(11):canimm.0342.2018. doi:10.1158/2326-6066.CIR-18-0342.
   PubMed Web of Science ®Google Scholar
• Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37(11):1351–60. doi:10.1038/s41587-019-0259-z.
   PubMed Web of Science ®Google Scholar
• Reiman D, Sha L, Ho I, Tan T, Lau D, Khan AA. Integrating RNA expression and visual features for immune infiltrate prediction. Pac Symposium Biocomput Pac Symposium Biocomput. 2019;24:284–95.
   PubMedGoogle Scholar
• Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Vareki SM. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. Oncoimmunology. 2018;7(10):e1498439. doi:10.1080/2162402X.2018.1498439.
   PubMed Web of Science ®Google Scholar
• Veerdonk FL, Graaf DM, Joosten LA, Dinarello CA. Biology of IL‐38 and its role in disease. Immunol Rev. 2017;281(1):191–96. doi:10.1111/imr.12612.
   Web of Science ®Google Scholar
• Palomo J, Troccaz S, Talabot-Ayer D, Rodriguez E, Palmer G, Budunova I. The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. PLos One. 2018;13(3):e0194667. doi:10.1371/journal.pone.0194667.
   PubMed Web of Science ®Google Scholar
• Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. J Clin Invest. 2018;128(2):805–15. doi:10.1172/JCI96113.
   PubMed Web of Science ®Google Scholar
• Rudloff I, Godsell J, Nold‐petry CA, Harris J, Hoi A, Morand EF, Nold MF. Brief report: interleukin‐38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(12):3219–25. doi:10.1002/art.39328.
   PubMed Web of Science ®Google Scholar
• Xie C, Yan W, Quan R, Chen C, Tu L, Hou X, Fu Y. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. Cytokine. 2020;127:154963. doi:10.1016/j.cyto.2019.154963.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Accardo‐palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, Raimondo S, Carubbi F, Valesini G, Giacomelli R, et al. Interleukin-36α axis is modulated in patients with primary Sjögren’s syndrome. Clin Exp Immunol. 2015;181(2):230–38. doi:10.1111/cei.12644.
   PubMed Web of Science ®Google Scholar
• Gao X, Chan PKS, Lui GCY, Hui DSC, Chu I-T, Sun X, Tsang M-M, Chan BCL, Lam C-K, Wong C-K. Interleukin-38 ameliorates poly(I: c) induced lung inflammation: therapeutic implications in respiratory viral infections. Cell Death & Disease. 2021;12(1):53. doi:10.1038/s41419-020-03283-2.
   PubMed Web of Science ®Google Scholar
• Sun X, Hou T, Cheung E, Iu T-T, Tam V-H, Chu I-T, Tsang M-M, Chan P-S, Lam C-K, Wong C-K. Anti-inflammatory mechanisms of the novel cytokine interleukin-38 in allergic asthma. Cell Mol Immunol. 2019;17(6):1–16. doi:10.1038/s41423-019-0300-7.
   PubMed Web of Science ®Google Scholar
• Rafie MZ, Esmaeilzadeh A, Ghoreishi A, Tahmasebi S, Faghihzadeh E, Elahi R. IL-38 as an early predictor of the ischemic stroke prognosis. Cytokine. 2021;146:155626. doi:10.1016/j.cyto.2021.155626.
   PubMed Web of Science ®Google Scholar
• Lambertsen KL, Finsen B, Clausen BH. Post-stroke inflammation—target or tool for therapy? Acta Neuropathol. 2019;137(5):693–714. doi:10.1007/s00401-018-1930-z.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus–related and –unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–19. doi:10.1200/JCO.2007.14.1713.
   PubMed Web of Science ®Google Scholar
• Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, et al. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology. 2017;6(6):e1322238. doi:10.1080/2162402X.2017.1322238.
   PubMed Web of Science ®Google Scholar
• Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-Cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016;22(12):3005–15. doi:10.1158/1078-0432.CCR-15-2762.
   PubMed Web of Science ®Google Scholar
• Sakimura C, Tanaka H, Okuno T, Hiramatsu S, Muguruma K, Hirakawa K, Wanibuchi H, Ohira M. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. J Surg Res. 2017;215:74–82. doi:10.1016/j.jss.2017.03.033.
   PubMed Web of Science ®Google Scholar
• Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Resp Crit Care. 2014;189(7):832–44. doi:10.1164/rccm.201309-1611OC.
   PubMed Web of Science ®Google Scholar
• Petitprez F, de RA, Keung EZ, Chen T-W, Sun C-M, Calderaro J, Jeng Y-M, Hsiao L-P, Lacroix L, Bougoüin A, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):1–5. doi:10.1038/s41586-019-1906-8.
   Web of Science ®Google Scholar
• Domblides C, Rochefort J, Riffard C, Panouillot M, Lescaille G, Teillaud J-L, Mateo V, Dieu-Nosjean M-C. Tumor-associated tertiary lymphoid structures: from basic and clinical knowledge to therapeutic manipulation. Front Immunol. 2021;12:698604. doi:10.3389/fimmu.2021.698604.
   PubMed Web of Science ®Google Scholar
• Chelvanambi M, Weinstein AM, Storkus WJ. Tumor Microenvironment, the Role of Interleukins – Part a. Adv Exp Med Biol. 2020;1240:95–110.
   PubMed Web of Science ®Google Scholar
• Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLos One. 2018;13(11):e0206223. doi:10.1371/journal.pone.0206223.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(4):1014–30.e19. doi:10.1016/j.cell.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144–53. doi:10.1038/nm.4466.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, Donia M, Larsen MS, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–65. doi:10.1038/s41586-019-1914-8.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. doi:10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting innate immunity in cancer therapy. Vaccines (Basel). 2021;9(2):138. doi:10.3390/vaccines9020138.
   PubMed Web of Science ®Google Scholar
• Collado-Torres L, Nellore A, Kammers K, Ellis SE, Taub MA, Hansen KD, Jaffe AE, Langmead B, Leek JT. Reproducible RNA-seq analysis using recount2. Nat Biotechnol. 2017;35(4):319–21. doi:10.1038/nbt.3838.
   PubMed Web of Science ®Google Scholar
• Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JML, Hlatky L, Hahnfeldt P, Mac Gabhann F. Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol. 2014;10(8):e1003800. doi:10.1371/journal.pcbi.1003800.
   PubMed Web of Science ®Google Scholar
• Zavrakidis I, Jóźwiak K, Hauptmann M. Statistical analysis of longitudinal data on tumour growth in mice experiments. Sci Rep-Uk. 2020;10(1):9143. doi:10.1038/s41598-020-65767-7.
   PubMed Web of Science ®Google Scholar
• Vaidya VG, Alexandro FJ. Evaluation of some mathematical models for tumor growth. Int J Biomed Comput. 1982;13(1):19–35. doi:10.1016/0020-7101(82)90048-4.
   PubMedGoogle Scholar